GSK Unveils Breakthrough Jemperli for Advanced dMMR/MSI-H Rectal Cancer
GSK unveils breakthrough Jemperli (dostarlimab) for patients with locally advanced mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) rectal cancer.
Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, serves as the cornerstone of GSK’s immuno-oncology research and development programme.
It is being investigated in combination with carboplatin and paclitaxel for adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.
Additionally, Jemperli is approved as a monotherapy for adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed after prior treatment with platinum-based regimens.
Currently, the standard care for patients with dMMR/MSI-H locally advanced rectal cancer includes chemotherapy and radiation followed by surgical removal of the tumour and parts of the intestine or surrounding tissue.
While this approach yields positive initial results for most patients, nearly one-third succumb to metastatic disease. Moreover, the combination of surgery and chemoradiotherapy can significantly affect long-term quality of life, causing complications such as bowel, urinary, and secondary cancers, and infertility.
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Jemperli (dostarlimab) for treating patients with locally advanced mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) rectal cancer.
